This press release has no medical significance. It is borderline irresponsible for Gilead to release such information, albeit they seem to have carefully qualified everything they say so as to avoid liability.
Irresponsible to who? This doesnt get the drug approved. They're running large phase 3s and all, which is what let's them put the drug on the market. In the mean time compassionate use data is useful to know.
